Page 1 of 5 12345 LastLast
Results 1 to 10 of 43

Thread: Asterias / cohort two

  1. #1

  2. #2
    Totally Awesome News!

    The patient treated at Shepherd Center has completed a three-month post-injection assessment and has progressed from a complete ASIA Impairment Scale (AIS) A injury to an incomplete AIS C injury. The principal investigator at Shepherd Center, Medical Director Donald Peck Leslie, M.D., said, This progress in the first patient is very encouraging and is observed in fewer than 5 percent of our AIS A patients at this stage of their recovery.


    The second cohort in this clinical trial will enroll five patients, who will receive 10 million AST-OPC1 cells.

  3. #3
    Are these the OPCs that Ed Wirth talked about at W2W?

    A to C would be impressive, if it can be shown that the cells were the reason this happened and not spontaneous recovery.

    I'm going to have to go back and look more at their trial now.

  4. #4
    Quote Originally Posted by tomsonite View Post
    Are these the OPCs that Ed Wirth talked about at W2W?

    A to C would be impressive, if it can be shown that the cells were the reason this happened and not spontaneous recovery.

    I'm going to have to go back and look more at their trial now.
    Yes, these are the ones. This is the sub-acute trial where patients can be up to 30 days post. This was just the initial 2 million cell safety dose patient at 3 month check up. The next cohort will ramp up to 10 million and then a group will get 20 million.


    http://asteriasbiotherapeutics.com/asterias-biotherapeutics-to-begin-dose-escalation-in-the-scistar-phase-12a-clinical-trial-of-ast-opc1-for-complete-cervical-spinal-cord-injury/
    Last edited by GRAMMY; 10-20-2015 at 12:45 PM.

  5. #5
    For anyone following the Asterias trial in this thread, here is a LINK to a couple very recent video presentations. One is by Jane Lebkowski, Asterias Biotherapeutics’ VP of Research and Development that spoke to CIRM’s governing Board about the company’s CIRM-funded clinical trial for spinal cord injury. Richard Lajara, the fourth participant in a previous trial also gives a patient’s perspective.

    The second video is Stem Cells on the Mesa with Jane Lebkowski. LINK

  6. #6
    Might be a good week to monitor their website.

  7. #7
    Anything for us? I couldn't find anything on their website. I hope I just missed it.

  8. #8
    Senior Member lunasicc42's Avatar
    Join Date
    Oct 2004
    Location
    Lutz, Fl USA*********C456
    Posts
    2,329
    Quote Originally Posted by Chaz19 View Post
    Anything for us? I couldn't find anything on their website. I hope I just missed it.

    I think most people just care about this trial for sake of them chugging along with the sci community but as far as this helping us chronics...it really doesn't even really have much to do with us as far as I know
    "That's not smog! It's SMUG!! " - randy marsh, southpark

    "what???? , you don't 'all' wear a poop sac?.... DAMNIT BONNIE, YOU LIED TO ME ABOUT THE POOP SAC!!!! "


    2010 SCINet Clinical Trial Support Squad Member
    Please join me and donate a dollar a day at http://justadollarplease.org and copy and paste this message to the bottom of your signature

  9. #9
    If it progresses and criteria gets wider it may one day.
    Quote Originally Posted by lunasicc42 View Post
    I think most people just care about this trial for sake of them chugging along with the sci community but as far as this helping us chronics...it really doesn't even really have much to do with us as far as I know

  10. #10
    Quote Originally Posted by c473s View Post
    If it progresses and criteria gets wider it may one day.
    The news a couple weeks ago wasn't bad either. LINK

    FREMONT, Calif. May 24, 2016 –
    Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced new positive long-term follow-up results from its Phase 1 clinical trial assessing the safety of AST-OPC1 (oligodendrocyte progenitor cells) in patients with spinal cord injury.

Similar Threads

  1. Replies: 38
    Last Post: 06-07-2018, 10:56 AM
  2. Replies: 1
    Last Post: 04-16-2015, 06:07 PM
  3. Replies: 4
    Last Post: 08-29-2014, 04:23 PM
  4. Replies: 6
    Last Post: 04-22-2013, 11:06 PM
  5. Jin, et al. (2003). Birth cohort effects in multiple sclerosis.
    By Wise Young in forum Multiple Sclerosis Research
    Replies: 0
    Last Post: 04-13-2003, 10:11 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •